Richard Chin - Net Worth and Insider Trading

Richard Chin Net Worth

The estimated net worth of Richard Chin is at least $14 Million dollars as of 2024-05-13. Richard Chin is the CEO of Kindred Biosciences Inc and owns about 1,534,271 shares of Kindred Biosciences Inc (KIN) stock worth over $14 Million. Details can be seen in Richard Chin's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Richard Chin has not made any transactions after 2021-08-02 and currently still holds the listed stock(s).

Transaction Summary of Richard Chin

To

Richard Chin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Richard Chin owns 4 companies in total, including Kindred Biosciences Inc (KIN) , SELLAS Life Sciences Group Inc (SLS) , and EOM Pharmaceutical Holdings Inc (IMUC) among others .

Click here to see the complete history of Richard Chin’s form 4 insider trades.

Insider Ownership Summary of Richard Chin

Ticker Comapny Transaction Date Type of Owner
KIN Kindred Biosciences Inc 2021-08-02 director & Chief Executive Officer
SLS SELLAS Life Sciences Group Inc 2009-04-23 director
IMUC EOM Pharmaceutical Holdings Inc 2014-06-13 director
2005-08-24 director

Richard Chin Latest Holdings Summary

Richard Chin currently owns a total of 1 stock. Richard Chin owns 1,534,271 shares of Kindred Biosciences Inc (KIN) as of August 2, 2021, with a value of $14 Million.

Latest Holdings of Richard Chin

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KIN Kindred Biosciences Inc 2021-08-02 1,534,271 9.25 14,192,007

Holding Weightings of Richard Chin


Richard Chin Form 4 Trading Tracker

According to the SEC Form 4 filings, Richard Chin has made a total of 3 transactions in Kindred Biosciences Inc (KIN) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Kindred Biosciences Inc is the sale of 40,000 shares on August 2, 2021, which brought Richard Chin around $368,400.

Insider Trading History of Richard Chin

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Richard Chin Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Richard Chin Ownership Network

Ownership Network List of Richard Chin

No Data

Ownership Network Relation of Richard Chin


Richard Chin Owned Company Details

What does Kindred Biosciences Inc do?

Who are the key executives at Kindred Biosciences Inc?

Richard Chin is the director & Chief Executive Officer of Kindred Biosciences Inc. Other key executives at Kindred Biosciences Inc include 10 percent owner Park West Asset Management Llc , Chief Financial Officer Wendy Wee , and Chief Scientific Officer Hangjun Zhan .

Kindred Biosciences Inc (KIN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kindred Biosciences Inc (KIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kindred Biosciences Inc (KIN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kindred Biosciences Inc (KIN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Kindred Biosciences Inc Insider Transactions

No Available Data

Richard Chin Mailing Address

Above is the net worth, insider trading, and ownership report for Richard Chin. You might contact Richard Chin via mailing address: C/o Oxigene, Inc., 230 Third Avenue, Waltham Ma 02451.

Discussions on Richard Chin

No discussions yet.